Aims To evaluate the effectiveness of automated symptom and side effect monitoring on quality of life among individuals with symptomatic diabetic peripheral neuropathy.
Introduction
An estimated 5.5 million people with diabetes have symptomatic diabetic peripheral neuropathy (hereafter neuropathy) [1] . Characterized by pain, burning, tingling and electric shock sensations in the extremities, neuropathic pain can negatively impact a person's quality of life and is responsible for nearly one-third of all diabetes-related healthcare costs, approximately US $5À14 billion per year [1] [2] [3] . Although neuropathy is not curable, its development can be slowed via improved glycaemic control and the long-term impact may be moderated by effective symptom treatment, particularly pain [2] [3] [4] [5] [6] . However, there is increasing evidence that neuropathy is underdiagnosed and treated in primary care [7, 8] .
Clinical guidelines recommend beginning treatment with select medications (e.g. tricyclic antidepressants, gabapentinoids) and gradually titrating the dose to achieve a balance between symptom relief and side effects [4] [5] [6] . For the estimated 50% of individuals with active symptoms, frequent communication with primary care providers may facilitate early diagnosis and treatment of neuropathy [2] . However, there are numerous barriers to effective communication with primary care providers, including low health literacy, language barriers and a reluctance on the part of individuals with neuropathy to discuss their symptoms [9, 10] . In addition, the limited time available during primary care visits can hamper discussion of person-reported concerns about neuropathy symptoms and their treatment.
To address these individual, provider and temporal barriers to the effective treatment of neuropathy symptoms, the Diabetes Telephone Study [11] was designed as a cluster randomized controlled trial (RCT) to test whether automated monitoring of participants' treatment experiences and feedback to physicians using interactive voice response technology and an electronic health record (EHR) could support communication with primary care providers, facilitate guidelineconsistent care, and result in improvements in quality of life and symptoms for individuals with neuropathy compared with usual care.
Participants and methods

Design overview
We conducted a pragmatic, cluster RCT in primary care clinics within the Kaiser Permanente Northern California health system between July 2014 and July 2016 [11] . The clusters were primary care physicians treating people with diabetes. We designed the intervention to work under usual clinical conditions, minimize exclusions and employ technologies routinely used in clinical practice, i.e. interactive voice response technology which allows individuals to interact with a computerized voice, and the EHR [12] .
The intervention was designed and evaluated in close collaboration with three individuals with neuropathy being cared for in our settings and three clinician stakeholders who were active members of the research team [11] . In addition, we received ongoing feedback from two community-based neuropathy support groups. The Kaiser Permanente Northern California Institutional Review Board approved all research procedures and the study is registered at ClinicalTrials.gov (CE-1304-7250). Consent was waived for physicians and written consent was waived for individuals with neuropathy in lieu of phone consent.
Study setting and participants
Kaiser Permanente Northern California is a multi-specialty healthcare system with 21 medical centres that serve more than 4 million people in northern California. Usual care for people with diabetes includes a robust panel management approach that leverages performance feedback, system-wide efficiencies, disease registries and evidence-based practice leveraging an integrated EHR [13] .
All primary care physicians treating at least one person with neuropathy enrolled in the Kaiser Permanente Northern California Diabetes Registry in the prior year were eligible for randomization. People with diabetes were potentially eligible for the study if they were 18 years old when they started a neuropathy medication, screened positive for neuropathy symptoms (according to brief questionnaire administered during routine primary care visits and available for > 85% of all people with diabetes), continuously enrolled in our setting during the 12 months prior to starting study medications, and spoke English or Spanish. We excluded individuals who had a diagnosis of gestational diabetes, dementia or substance abuse disorder during the previous 12 months because medication strategies may differ for these individuals. In addition, we excluded individuals who had any opioid use during the 90 days prior to starting first-line neuropathy treatment because opioid use in the near-term may indicate prior treatment failures [4] .
Randomization and participant recruitment
We randomized 1834 Kaiser Permanente Northern California primary care physicians treating adults with diabetes in a ratio of one to one to the intervention and control groups on 11 July 2014. Of those randomized, 1714 physicians had people on their lists who met the initial study criteria. In October 2014, we notified these physicians that people under their care might be approached about the study and invited the physicians to What's new?
• Frequent communication between individuals with diabetic peripheral neuropathy and primary care providers about symptoms and medication side effects is critical to optimizing medication dosing to treat painful diabetic peripheral neuropathy. Yet, there are considerable barriers to effective communication.
• This cluster randomized controlled trial found that a brief intervention to automatically monitor personreported data on symptoms and side effects, and provide the information to physicians via an electronic health record was not effective in improving the outcomes valued by individuals with neuropathy.
• Alerts alone are unlikely to change provider behaviour related to treatment intensification. More intensive interventions focused on individual activation or provider education may be more effective in changing prescribing behaviour and improving outcomes.
ª 2018 Diabetes UK opt out any individual due to illness or other factors that would make them ineligible for participation. We then used the HER to prospectively identify individuals who met the above inclusion criteria and who were newly prescribed (i.e. no use in the previous 12 months) one of 10 medications commonly used to treat neuropathy symptoms in this setting (amitriptyline, nortriptyline, imipramine, desipramine, duloxetine, paroxetine, citalopram, pregabalin, venlafaxine or gabapentin) during the last 2 weeks. The total enrolment period was September 2014 to November 2015. Recruitment letters in English and Spanish were sent to 5716 people identified by a computer algorithm as possibly having neuropathy symptoms and who started a study medication within the past 2 weeks. Interviewers, blinded to treatment assignment, called individuals~1 week later to assess eligibility for the trial and, among those deemed eligible, to obtain phone consent and to conduct the baseline interview. Individuals with neuropathy and their primary care providers were unaware of their treatment status during recruitment. Within the study team, only the main analyst, the research assistant charged with entering participant data into the EHR, and the individual responsible for scheduling the interactive voice response calls, were aware of the participants' treatment status.
English-and Spanish-speaking interviewers were able to reach and screen 2203 people with diabetes to confirm eligibility. In addition, the interviewers excluded individuals based on other factors that may have impeded participation in the study (e.g. rotary phone). Individuals who could not be contacted within 56 days of starting treatment (maximum of 10 call attempts) were excluded from further recruitment calls. Specific reasons for ineligibility are described in Fig. 1 .
The intervention
Participants in the intervention arm received all usual care, plus three 5-min interactive voice response calls spaced 2 months apart over the 6 months following the start of neuropathy (Fig. 2) . These interactive calls systematically collected information on symptom relief, medication use, titration, discontinuation and side effects. Participant responses were then entered manually into the EHR by a trained research assistant. We created an algorithm to 'alert' physicians via a secure staff message when people under their care reported specific problems identified by our clinician partners as requiring physician intervention (i.e. dissatisfaction with symptom relief, side effects, discontinuation, or failing to start). No specific follow-up protocol was imposed for physician response at the request of these clinician partners to minimize disruptions in usual care. Responses from participants who reported none of these problems were entered into the EHR with no physician alert.
Control arm
Participants in the control arm received all usual care for diabetes and neuropathy, plus three non-interactive 2-3-min educational calls (i.e. physical activity, dietary changes, foot checks) in English and Spanish delivered over the same time intervals as the intervention calls. The goal of providing these non-interactive calls was to isolate the marginal impact of receiving an automated, diabetes-related phone call in the intervention arm.
Outcomes and follow-up
The primary outcome for this study was quality of life, a person-reported outcome that is highly associated with neuropathy symptoms, but rarely studied in drug trials [14] . We calculated quality of life using the Global Health Scale (e.g. general health status, social functioning), a 10-item PROMIS â (Patient-Reported Outcomes Measurement
Information System) questionnaire developed and validated in individuals with neuropathy [15] . We converted the Global Health Scale into the EQ-5D, a standardized instrument developed by the European Quality of Life (EuroQol) Group as a measure of health-related quality of life, using previously validated methods to ensure comparability with other studies [16] .
In addition to quality of life, we also evaluated changes in neuropathy symptoms, including pain interference (range = 40.7-77.0; 77 indicates maximum interference), sleep disruption (range: 32-84.2; higher score indicates maximum disruption), lower extremity functioning (range: 16.5-58.6; 58.6 indicates best possible functioning) and depressive symptoms (range: 38.2-81.3; 81.3 indicates worst possible symptoms). These measures were assessed using the NeuroQOL measurement system instruments that have been previously validated in individuals with neuropathy [17] .
All person-reported outcomes were collected by trained interviewers during 20-min phone interviews at~2 months (baseline) and again 8 months (follow-up) following treatment start. We hypothesized that automated monitoring and feedback of information on symptoms and side effects would result in clinically significant improvements in quality of life (EQ-5D = 0.074) and neuropathy symptoms [16, 17] .
In addition, we evaluated two process measures to assess changes in communication between people with neuropathy and their primary care providers, and dosing. We used the six-item Doctor Communication Composite questionnaire from the Consumer Assessment of Health Plans (CAHPS) Survey (min = 4; max = 24; 24 indicates best communication) to assess individual's satisfaction with the quality of communication with their primary care provider over the last 12 months [18] . To evaluate medication dosing, we used EHR data to calculate whether the participant ever received the minimum effective dose of neuropathy medication [7, 8] . Specifically, for each medication, we assessed whether the maximum daily dose ever reached or surpassed the dose found to be therapeutically effective in clinical trials [7] . This measure was assessed only for the 12 months following the first observed prescription.
Sub-group analyses
Variation in treatment effect by level of shared decisionmaking
Our protocol included a pre-planned analysis of differences in effect of the intervention by the level of shared decisionmaking at baseline, measured using the nine-item Shared Decision Making Questionnaire (SDM-Q-9; six point scale: 0, completely disagree; 5, completely agree) [19] . We hypothesized that the intervention would be more effective in participants who perceived a high level of shared decisionmaking between themselves and their physician.
Statistical analysis
The unit of analysis in this cluster RCT is the primary care physician. On average, physicians had fewer than two people enrolled in the study.
Nevertheless, to formally account for the dependence of individual's measurements clustered within physicians and (1), was on the no contact registry (1), was no longer a Kaiser Permanente member (16), was prescribed a study drug for a condition other than neuropathy (290), was unable to communicate in English or Spanish (1), or was unreachable or unavailable during the length of the study (3).
because our main analysis was conducted at the person with neuropathy level, we employed generalized estimating equations (GENMOD procedure in SAS â ) [20] with robust standard errors and an independent correlation structure to estimate intervention effects. Our models estimated the change from baseline in each of the person-reported outcomes of interest. The resulting treatment effects provided an estimate of the difference in the change (i.e. the difference in difference) between individuals in the treatment group relative to controls. Unlike random effects models, generalized estimating equations does not require a normality assumption and these regression models therefore provide valid estimation of treatment effects and associated standard errors even when the assumptions about the correlation structure are wrong [21] . In sensitivity analyses, the estimates of treatment effects and associated standard errors were robust to changes in the choice of correlation structure, level of analysis (physician vs. person receiving treatment) and whether the outcome was treated as a change from baseline or a repeated measure. Although the trial took part in multiple medical centres, individuals with diabetic peripheral neuropathy and physicians can receive care and practice across in multiple medical centres. Therefore, we did not adjust for medical centre in the analysis.
No additional covariates were included in the main analyses due to the high degree of similarity between the treatment and control groups with respect to baseline characteristics following randomization. Models estimating heterogeneity in treatment effects included the shared decision-making score as a continuous variable and an interaction between this measure and the treatment indicator for the primary outcomes of interest ( Table 1) .
The analyses were based on the intent-to-treat and complete case analysis principles, using only data from participants with complete baseline and follow-up outcome measurements regardless of whether they completed all three intervention calls [22] . A two-sided test of each null hypothesis that the mean change in outcomes in the treated arm is equal to that of the control arm was derived from the test that the slope of each linear model is equal to zero.
All participants were required to complete the quality of life and sleep disruption surveys. However, to minimize participant burden, we only administered the pain, depressive symptom and lower extremity functioning reports to individuals who indicated problems with these symptoms in the quality of life survey. To account for this intentional skipping pattern in the statistical analysis, we imputed the data by setting outcomes to their best possible value by subtracting 0,1 from the minimum value for pain interference, lower extremity functioning and depressive symptoms.
Contextual considerations
We conducted a limited survey with physicians to assess awareness and acceptance of the intervention. We also assessed physicians' perception of the intervention's potential utility to aid decision-making related to neuropathy care, as well as its use for other conditions. We randomly selected 50 physicians in the intervention arm who received at least one alert during the study to receive an email from the principal investigator. We aimed to recruit 30 physicians to participate in the follow-up survey. This survey group was not planned as a representative sample, but as a brief assessment of physician attitudes toward their experience of intervention.
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Power
With a type I error alpha of 0.05 and a type II error beta of 0.20, we estimated that the minimum detectable effect, i.e. the difference in EQ-5D change from baseline to end of study between the two arms, was 0.017. This calculation was conservative in the sense that it concerned an analysis in which only outcomes from the first person with neuropathy for each randomized physician would be considered (cluster of size 1). The calculation assumed that a minimum of 118 eligible participants would be enrolled per month with a drop-out rate of 40% (minimum 850 participants; 425 per arm), and a standard deviation for the outcome of 0.143. Thus, we anticipated having > 80% power to detect an effect that was smaller than the published clinically meaningful differences in EQ-5D change of 0.074 [16, 23] .
Results
Participants
Of the 5716 individuals contacted, 2,03 were screened for eligibility. Compared with those who were screened, those who were not screened were slightly younger [66. 3 (12. 2) vs. 67.0 (11.8) years; P = 0.051], more likely to be Asian (16% vs. 8%) and less likely to be white (46% vs. 57%) (P < 0.0001). Among the 2203 who were screened, we identified 1535 people with diabetes who were eligible for participation in the main study, 83% (1270) of whom consented to participate (Fig. 1) . Reasons for declining consent could be multiple and included: lack of interest (173), being too busy (44), and being too sick to participate (52). Our retention rate (proportion completing follow-up) was 93%. Compared with people who dropped out, participants with complete data were more likely to be female (54% vs. 41%; P = 0.299), with a slightly higher baseline quality of life (mean EQ-5D: 0.657 AE 0.092 vs. 0.634 AE 0.100; P = 0.0437) and had slightly higher average lower extremity functioning scores (48.359 AE 11.439 vs. 45.660 AE 12.598; P = 0.0519 (Table S1) .
Baseline characteristics of the study sample are presented in Table 1 . The mean age was 67 (SD 11.7) years and 53% were female. The sample was racially and ethnically diverse (57% white, 8% Asian, 13% black, 20% Hispanic) and 17% were living in economically depressed areas. Fifteen per cent of participants had an HbA 1c > 74 mmol/ml (> 9%). There were no statistically significant differences in baseline characteristics between the intervention and control groups.
Intervention uptake and fidelity
Of the 1252 participants who completed the baseline assessment, 1248 completed the first call (100% control; 98% intervention). Only 53% of the intervention participants completed all three calls compared with 60% of control participants. More than 80% of participants completed at least one post-baseline call (85% control; 83% intervention). The average intervention call lasted 5 min, compared with 4 min for the control calls (Table S2) .
Trial outcomes
The intervention was not effective in improving quality of life (estimated difference in change between treatment and control of À0.002, SE 0.005; P = 0.623), diabetic peripheral neuropathy symptoms, effective dosing (53% treatment compared with 48% control; 95% CI À0.11 to 0.38) or communication (À0.45; À0.97 to 0.07) ( Table 2 ). In the subgroup analyses, no significant interactions related to shared decision-making were observed (Table S3 ). The independent safety monitor reported no adverse events or unintended effects attributable to the trial.
Participant experiences with diabetic peripheral neuropathy medications
Among participants in the intervention group, 74% reported side effects, medication discontinuation or dissatisfaction with treatment during the first interactive voice response (IVR) call, triggering a physician alert. Side effects were the most commonly reported problem (<50%). Among participants who were actively using the medication at the time of the first call, > 95% reported taking it once a day and 33% reported self-titrating the medication dose.
Clinical context for the intervention
We successfully recruited 31 of 50 physicians who received an alert to report on their experiences with the intervention. Only seven recalled seeing the EHR alert, although 13 reported being aware or very aware of the study. Of those who recalled seeing the reports, most did not think the information was actionable, would change how they provided care or could not have been obtained directly from the person with neuropathy. Most (23/31) of the physicians surveyed reported that the automated monitoring strategy could be useful for other conditions where 'answers are black and white' such as diabetes and hypertension, and for medications 'with serious side effects' such as warfarin.
Discussion
In this pragmatic RCT, automated monitoring and feedback of symptoms and side effects related to diabetic peripheral neuropathy treatment as reported by individuals with the condition was not effective in improving outcomes. Our study findings are in conflict with prior studies demonstrating positive effects of automated monitoring in diabetes and chronic pain (non-diabetic peripheral neuropathy pain) using IVR [24] [25] [26] [27] [28] . One possible explanation for this difference is that compared with prior interventions, our intervention did not dictate a specific protocol for physicians and was less intensive (three calls over 6 months). Our effort to minimize physician burden may have weakened the potential impact of the intervention. However, it is also important to note that while participant reports triggered an alert in 74% of all calls, most physicians only had one person enrolled in the trial. Therefore, it is not surprising that individual physicians did not recall this specific alert among the many they receive on a daily basis. Further, low intervention fidelity (~50% completed all three calls) may have contributed to the lack of intervention effect. In addition, this intervention was conducted within a system with a high-functioning diabetes management programme [13] , which may have made it harder to have a clinically important impact over and above usual care.
Our findings suggest that in cases like diabetic peripheral neuropathy where outcomes related to the natural progression of the disease (e.g. symptoms) are considered more acceptable than outcomes that are induced by treatment (e.g. side effects), physicians may tend toward more conservative treatment strategies or intentional under-dosing [29] [30] [31] [32] . In the absence of highly effective treatments, the impact of interventions to improve use of existing treatments on physician prescribing is likely to be limited. Research is needed to identify treatment pathways that yield greater efficacy with reduced side effects, including non-pharmacological treatments [33] [34] [35] .
Our findings related to experiences with treatment as reported by individuals with diabetic peripheral neuropathy are, to our knowledge, the first published evidence regarding rates of self-titration of diabetic peripheral neuropathy medication. We found that~30% of participants reported self-titrating, which may indicate a potential opportunity for self-focused interventions to improve dosing [36, 37] . This may be especially important given the challenges we observed with physician recall of participant-reported data within the context of EHR data overload and alert fatigue. However, high rates of side effects and recent reports of the potential for abuse of gabapentinoids suggest such interventions in diabetic peripheral neuropathy would need to first identify which individuals are most likely to benefit from and not be harmed by these treatments [38] .
Our study has several limitations that deserve consideration. First, our findings may not extend to other types of delivery systems or to subgroups that we explicitly excluded from participation (e.g. dementia). We endeavoured to include a diverse cohort of people with diabetes and the technologies we employed are widely available across diverse systems of care [27, 28] , although we did not include an assessment of participants' satisfaction with the IVR system, and how it might be improved for future interventions. In addition, some participants may have been taking study medications for conditions other than diabetic peripheral neuropathy, which may have diluted the impact of the neuropathy-focused intervention. Further, we assessed quality of communication over the prior 12 months and may have captured aspects of physician interactions with people with neuropathy that are not specific to the 8-month intervention period. Additionally, given physicians' general lack of recall of the study EHR messages, a more intensive roll-out of the study would have been advisable. Lastly, we conducted an intent to treat analysis, which risks underestimating treatment effects by not accounting for partial compliance with the intervention. Our study had several strengths that contributed to the validity of the results, including the large sample size, the high response rate, and low rates of drop-outs and missing data. Also, this study demonstrated the feasibility of automated monitoring of treatment effects using IVR and feedback to providers via an EHR, which can be tested for other types of interventions (e.g. activation) and clinical goals (e.g. medication safety).
Conclusions
Symptomatic diabetic peripheral neuropathy is one of the most common complications of diabetes and one of the most difficult to treat due to the variable efficacy and tolerability of available treatments [4] [5] [6] 10] . As one of the first studies to employ automated monitoring to improve outcomes for people with neuropathy, this study is an important step in developing new ways to address the unmet needs of this population. Although IVR technology is widely available within health systems [28] , it may be more effective if focused on individual activation (e.g. self-titration) or coupled with provider education about which individuals are most likely to benefit from available treatments and safe prescribing practices. In addition, our study demonstrates the challenges in finding a balance between intervention intensity and acceptance and adoption in real-world settings. Given the high costs of under-treatment of diabetic peripheral neuropathy symptoms for individuals and health systems [1] [2] [3] , inaction is not an option and evidence-based strategies are needed to help people with diabetic peripheral neuropathy and clinicians to balance the potential benefits and harms of treatment. 
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